Susceptibility

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Robert K. Flamm, Leonard R. Duncan, Kamal A. Hamed, Jennifer I. Smart, Rodrigo E. Mendes, Michael A. Pfaller
DOI: 10.1128/AAC.02566-19

Article Figures & Data

Figures

Tables

  • TABLE 1

    Antimicrobial activity of ceftobiprole tested against the main species and groups from skin and skin structure infections

    TABLE 1

    • ↵a ESBL, extended-spectrum β-lactamase.

    • ↵b Greater than the highest concentration tested.

    • ↵c These isolates met the MIC criteria for screening of β-lactamase-encoding genes (36) and contained an ESBL gene in the absence of a carbapenemase gene (see Materials and Methods).

  • TABLE 2

    Activity of ceftobiprole and comparator agents when tested against the major groups of Gram-positive bacteria from skin and skin structure infections in the United States (2016–2018)a

    TABLE 2

    • ↵a S, susceptible; I, intermediate; R, resistant; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.

    • ↵b Intermediate interpreted as susceptible-dose dependent.

    • ↵c Using other than pneumonia breakpoints.

    • ↵d FDA breakpoints accessed January 2019.

    • ↵e Organisms include: Streptococcus agalactiae (142), Streptococcus canis (3), Streptococcus dysgalactiae (41), Streptococcus pyogenes (268).

    • ↵f Uncomplicated urinary tract infections only.

    • ↵g FDA breakpoints accessed January 2019 applied to all E. faecalis but approved for vancomycin-susceptible isolates only.

    • ↵h Organisms include: Staphylococcus capitis (2), Staphylococcus caprae (2), Staphylococcus epidermidis (63), Staphylococcus haemolyticus (7), Staphylococcus hominis (3), Staphylococcus intermedius (1), Staphylococcus lugdunensis (90), Staphylococcus pseudintermedius (5), Staphylococcus saprophyticus (1), Staphylococcus schleiferi (1), Staphylococcus simulans (5), Staphylococcus warneri (1), Staphylococcus xylosus (1).

    • ↵i Interpretive criteria as published by CLSI 2019 and EUCAST 2019.

  • TABLE 3

    Activity of ceftobiprole and comparator agents when tested against the major groups of Gram-negative bacteria from skin and skin structure infections in the United States (2016–2018)a

    TABLE 3

    • ↵a S, susceptible; I, intermediate; R, resistant; ESBL, extended-spectrum β-lactamase.

    • ↵b Organisms include: Citrobacter amalonaticus (1), C. amalonaticus/farmeri (3), Citrobacter farmeri (1), Citrobacter freundii (8), C. freundii species complex (43), Citrobacter koseri (31), Cronobacter sakazakii (1), Edwardsiella tarda (1), Enterobacter aerogenes (57), E. cloacae (115), E. cloacae species complex (129), Escherichia coli (500), Escherichia hermannii (1), Klebsiella oxytoca (90), K. pneumoniae (192), Leclercia adecarboxylata (1), Lelliottia amnigena (1), Metakosakonia massiliensis (1), Morganella morganii (73), Pantoea agglomerans (2), Pantoea calida (1), Pantoea eucrina (1), Pluralibacter gergoviae (1), Proteus mirabilis (258), Proteus vulgaris (3), P. vulgaris group (16), Providencia rettgeri (14), Providencia stuartii (7), Serratia fonticola (1), Serratia liquefaciens (7), S. liquefaciens complex (1), S. marcescens (135), Pantoea spp. (2), Providencia spp. (1), Raoultella spp. (2).

    • ↵c Intermediate interpreted as susceptible-dose dependent.

    • ↵d FDA breakpoints accessed January 2019.

    • ↵e Interpretive criteria as published by CLSI 2019 and EUCAST 2019.

Back to top
Download PDF
Citation Tools
Print

Alerts
Email

KEYWORDS

ABSSSI
MRSA
SSTI
ceftobiprole
cephalosporin
skin
surveillance

Related Articles

Cited By...